Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZID
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZID
March 30, 2016 11:56 AM EDT
Acadia Pharma (NASDAQ: ACAD) is fading early gains after an FDA panel backed the company's Nuplazid.
Worries about a potential Black Box Warning could be to blame.
Shares are up 9.8% after opening up 20%.
...
More
March 30, 2016 10:44 AM EDT
Aegis Capital affirms Acadia Pharma (Nasdaq: ACAD) with a Buy rating and $54 price target following a positive FDA panel review of Acadia's Nuplazid on Tuesday.
Analyst Robert LeBoyer sees post-approval studies for Nuplazid, commenting, Following the results of the Phase III trial in 2013, Acadia met with the FDA and was encouraged to file based only on that trial. Its strong results... More
March 30, 2016 6:49 AM EDT
Needham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More
March 29, 2016 5:14 PM EDT
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinsons disease outweigh the risks of... More
March 29, 2016 3:37 PM EDT
Acadia Pharma (NASDAQ: ACAD) wins FDA panel backing for Nuplazid, according to Bloomberg.
...
More
